The biological role of the Fas/FasL system during tumor formation and progression (Q34766094)

4 August 2017

1 reference

title

The biological role of the Fas/FasL system during tumor formation and progression (English)

1 reference

4 August 2017

Ernst Reichmann

1

1 reference

4 August 2017

publication date

1 August 2002

1 reference

Seminars in Cancer Biology

4 August 2017

published in

1 reference

4 August 2017

volume

12

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

309-315

1 reference

Social controls on cell survival and cell death

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Programmed cell death and the control of cell survival: lessons from the nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Modularity in the TNF-receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

A novel domain within the 55 kd TNF receptor signals cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Activation interferes with the APO-1 pathway in mature human T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Metalloproteinase-mediated release of human Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

NF-kappa B-dependent Fas ligand expression

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Caspases: killer proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Autoproteolytic activation of pro-caspases by oligomerization

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Two CD95 (APO-1/Fas) signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

FAP-1: a protein tyrosine phosphatase that associates with Fas

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Inhibition of death receptor signals by cellular FLIP

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

A role for CD95 ligand in preventing graft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Lung lymphocyte elimination by apoptosis in the murine response to intratracheal particulate antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Fas-dependent tissue turnover is implicated in tumor cell clearance

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Death receptors: signaling and modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Apoptosis induced by death receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Steering anti-cancer drugs away from the TRAIL

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Cholangiocarcinomas express Fas ligand and disable the Fas receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

Pleiotropic cell-division defects and apoptosis induced by interference with survivin function

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

A genetic model for colorectal tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2802%2900017-2

7 January 2021

10.1016/S1044-579X(02)00017-2

Identifiers

DOI

1 reference

4 August 2017

1 reference